Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Suermann

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Versicherungsmedizin|October 1, 1990
[Trends in the risk factor profile between 1976 and 1988]D P Mertz, H Loewer, I Suermann
MMW, Munchener Medizinische Wochenschrift|August 25, 1978
[Clofibrate in type IIa hyperlipoproteinemia. Reduction of apolipoprotein B (author's transl)]D P Mertz, I Suermann, E Göhmann
Medizinische Klinik|February 23, 1979
[Influence of "prudent" diet and clofibrate upon apolipoprotein B in hyperlipoproteinemia type IIa (author's transl)]D P Mertz, I Suermann, E Göhmann
Medizinische Klinik|December 21, 1979
[The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)]D P Mertz, H Loewer, I Suermann
Medizinische Klinik|March 13, 1981
[Etofibrate lowers the atherosclerosis index]D P Mertz, I Suermann, E Göhmann
MMW, Munchener Medizinische Wochenschrift|October 5, 1979
[Lowering of the lipoproteins in type IIa hyperlipoproteinemia by means of bezafibrate. Comparison with clofibrate]D P Mertz, I Suermann, H Loewer
MMW, Munchener Medizinische Wochenschrift|June 8, 1979
[Hyperlipoproteinemia type IIa. Serum lipoprotein pattern as influenced by diet and clofibrate]D P Mertz, I Suermann, H Loewer, et al.
Die Medizinische Welt|March 19, 1982
[Diurnal activity rhythm of HMG-CoA reductase and decrease of lipid levels]D P Mertz, E Göhmann, I Suermann, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Versicherungsmedizin|October 1, 1990
[Trends in the risk factor profile between 1976 and 1988]D P Mertz, H Loewer, I Suermann
MMW, Munchener Medizinische Wochenschrift|August 25, 1978
[Clofibrate in type IIa hyperlipoproteinemia. Reduction of apolipoprotein B (author's transl)]D P Mertz, I Suermann, E Göhmann
Medizinische Klinik|February 23, 1979
[Influence of "prudent" diet and clofibrate upon apolipoprotein B in hyperlipoproteinemia type IIa (author's transl)]D P Mertz, I Suermann, E Göhmann
Medizinische Klinik|December 21, 1979
[The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)]D P Mertz, H Loewer, I Suermann
Medizinische Klinik|March 13, 1981
[Etofibrate lowers the atherosclerosis index]D P Mertz, I Suermann, E Göhmann
MMW, Munchener Medizinische Wochenschrift|October 5, 1979
[Lowering of the lipoproteins in type IIa hyperlipoproteinemia by means of bezafibrate. Comparison with clofibrate]D P Mertz, I Suermann, H Loewer
MMW, Munchener Medizinische Wochenschrift|June 8, 1979
[Hyperlipoproteinemia type IIa. Serum lipoprotein pattern as influenced by diet and clofibrate]D P Mertz, I Suermann, H Loewer, et al.
Die Medizinische Welt|March 19, 1982
[Diurnal activity rhythm of HMG-CoA reductase and decrease of lipid levels]D P Mertz, E Göhmann, I Suermann, et al.
Pageof 1